Recent news on Neutrospec

Palatin Technologies to Present at the Acumen Biofin 4th Annual ...  -  May 11, 2007
PR Newswire (press release),...need for regulatory approvals and commercial acceptance of its products, ability to recommence marketing and gain commercial acceptance of NeutroSpec(R)

Palatin Technologies to Present at the CIBC World Markets Annual ...  -  Apr 11, 2007
PR Newswire (press release),...need for regulatory approvals and commercial acceptance of its products, ability to recommence marketing and gain commercial acceptance of NeutroSpec(R)

Palatin Strikes a Landmark Deal  -  Feb 26, 2007
NJBIZ,Imaging agent NeutroSpec, Palatin’s only product on the market, was voluntarily recalled in December 2005 after it was implicated in adverse reactions among

Palatin Technologies, Inc. Reports Fiscal Year 2007 Second Quarter ...  -  Feb 9, 2007
PR Newswire (press release),In the current period, the Company recorded no royalty revenue related to commercial sales by Tyco Healthcare Mallinckrodt (Mallinckrodt) of NeutroSpec,

Palatin Technologies, Inc. Reports Fiscal Year 2007 Second Quarter ...  -  Feb 9, 2007
PR Newswire (press release),In December 2005, the Company and Mallinckrodt suspended all NeutroSpec sales and marketing activities. COSTS AND EXPENSES Total operating expenses for the

Palatin Technologies to Report Second Quarter, Fiscal Year 2007 ...  -  Feb 2, 2007
Earthtimes.org...need for regulatory approvals and commercial acceptance of its products, ability to recommence marketing and gain commercial acceptance of NeutroSpec(R)

Palatin Technologies to Hold Conference Call and Webcast to ...  -  Jan 31, 2007
Yahoo! News (press release)...need for regulatory approvals and commercial acceptance of its products, ability to recommence marketing and gain commercial acceptance of NeutroSpec®,

Palatin Technologies Presents At The 9th European Society For ...  -  Dec 6, 2006
Medical News Today (press release),...need for regulatory approvals and commercial acceptance of its products, ability to recommence marketing and gain commercial acceptance of NeutroSpec(R)

Palatin Technologies to Report First Quarter, Fiscal Year 2007 ...  Nov 7, 2006
...for regulatory approvals and commercial acceptance of its products, ability to recommence marketing and gain commercial acceptance of NeutroSpec(R), ability to ... -PR Newswire (press release), Palatin Technologies, Inc. Reports Fourth Quarter Fiscal Year End ...  Sep 13, 2006
...programs for products to treat obesity and congestive heart failure and lower revenue as a result of the December 2005 withdrawal from the market of NeutroSpec ... -MSN Money

Palatin Technologies to Present at UBS 2006 Global Life Sciences ...  Sep 22, 2006
...need for regulatory approvals and commercial acceptance of its products, ability to recommence marketing and gain commercial acceptance of NeutroSpec(R) and ... -PR Newswire

Palatin Technologies Presents At The 9th European Society For ...  -  Dec 6, 2006
Medical News Today (press release),...need for regulatory approvals and commercial acceptance of its products, ability to recommence marketing and gain commercial acceptance of NeutroSpec(R)

Movies show immune-cell tumor activity  -  Nov 21, 2006
Science Daily (press release)Wistar-Discovered Antibody Will Help Diagnose Appendicitis (July 12, 2004) -- NeutroSpec, a new imaging agent approved by the Food and Drug Administration

Steven Fischkoff, MD Joins Palatin Technologies as Vice President ...  Jul 28, 2006
...need for regulatory approvals and commercial acceptance of its products, ability to recommence marketing and gain commercial acceptance of NeutroSpec(R) and ... -PR Newswire



Palatin Technologies, Inc. Reports Fiscal Year 2006 Third Quarter ...  May 9, 2006
In the current period, the Company recorded no royalty revenue related to commercial sales by Mallinckrodt of NeutroSpec, versus $0.5 million in the quarter ... - PharmaLive.com

Palatin Technologies, Inc. Reports Fiscal Year 2006 Third Quarter ...  May 9, 2006
REVENUE AND ROYALTIES In the current period, the Company recorded no royalty revenue related to commercial sales by Mallinckrodt of NeutroSpec, versus $0.5 ... - PR Newswire

Palatin Technologies to Present at the Rodman & Renshaw 3rd Annual ...  May 11, 2006
...for regulatory approvals and commercial acceptance of its products, ability to recommence marketing and gain commercial acceptance of NeutroSpec® and ability ... - Yahoo! News





Abortion pill has potential to destroy women's lives  Apr 9, 2006
Consider this evidence: NeutroSpec, an imaging agent used to detect internal infections, was removed from the market after it was blamed for two deaths. ... - Patriot-News

Victims and Villains of RU-486  Mar 27, 2006
Drugs pulled by the FDA include NeutroSpec, Tysabri, Lotronex and Bextra. None of these resulted in as many deaths or complications as RU-486. ... - American Daily

RU-486 claims lives of two more women  Mar 29, 2006
Wright cited the drugs NeutroSpec, Tysabri, Lotronex and Bextra as examples of the FDA acting to pull drugs, some after just a few months on the market, with ... - ChristianExaminer

FDA Urged to Pull RU-486 after Two More Reported Deaths  Mar 17, 2006
For example, NeutroSpec, an imaging agent used to diagnose internal infections, was pulled from the market after it was linked to two deaths, 20 severe ... - CNSNews.com

CWA: RU-486 Claims Two More Women’s Lives  Mar 17, 2006
NeutroSpec, an imaging agent used to diagnose internal infections, was pulled from the market after being linked to two deaths, 20 severe reactions, and 46 ... - Dakota Voice

Abortion Pill Kills Two More Women  Mar 17, 2006
Drugs with fewer reported complications that the FDA has pulled include NeutroSpec, an imaging agent used to diagnose internal infections; Tysabri, a drug to ... - Playfuls.com



Palatin Technologies, Inc. Reports Fiscal Year 2006 Second Quarter ...  Feb 9, 2006
ED) and female sexual dysfunction (FSD), and inventory write-downs associated with the suspension of sales and marketing activities related to NeutroSpec(R), a ... - MSN Money

Tyco profits rise in first quarter  Feb 2, 2006
...higher costs. Tyco in December recalled its NeutroSpec radiology imaging agent in the US after it was linked to two deaths. Tyco ... - Northwest Herald,

Palatin Technologies, Inc. Reports Fiscal Year 2006 Second Quarter ...  09 Feb 2006
ED) and female sexual dysfunction (FSD), and inventory write-downs associated with the suspension of sales and marketing activities related to NeutroSpec(R), a ... - MSN Money

Tyco profits rise in first quarter  Feb 2, 2006
...higher costs. Tyco in December recalled its NeutroSpec radiology imaging agent in the US after it was linked to two deaths. Tyco ... - Northwest Herald

Tyco Posts $807 Mln 1st-Qtr Profit; Lowers Forecast (Update1)  Feb 2, 2006
...higher costs. Tyco in December recalled its NeutroSpec radiology imaging agent in the US after it was linked to two deaths. The ... - Bloomberg

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional